Biosimilars Market Insights, Potential Business Strategies, Mergers and Acquisitions, Revenue Analysis - P&S Intelligence

The market is majorly driven by rising prevalence of chronic diseases, increasing investment in research and development (R&D) activities by biopharmaceutical companies, extensive pipeline of biosimilars, growing geriatric population, and inexpensive nature of biosimilars as compared to reference drugs.

Geographically, Europe held the largest share, of 47.7%, in the biosimilars market in 2018. This is attributed to flexible regulatory framework, growing geriatric population, and rising R&D investment by biopharmaceutical companies in the region.

Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/biosimilars-market

The biosimilars market is anticipated to undergo fastest growth in North America, advancing at a CAGR of 32.7% during the forecast period. This can be mainly ascribed to rising geriatric population, increasing prevalence of chronic diseases, increase in R&D investments in the region.

According to the Population Reference Bureau report, “Aging in the United States”, the geriatric population is projected to reach more than double by 2060, which in turn, poses the requirement for management of old age-related diseases. Moreover, according to the Centers for Disease Control and Prevention (CDC), almost 60% of the U.S. adults have one or other chronic disease.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/biosimilars-market/report-sample

New product launches and strategic collaborations play an important role in expansion of the biosimilars market. For instance, Amgen Inc. and EnteraBio Ltd. announced a collaboration to develop orally-administered formulation of biologics in 2018. This shows that companies are willing to invest in biologics, which in turn, is expected to be a major driving factor for the growth of the market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=biosimilars-market

In another strategic move, Celltrion Inc. in partnership with Teva Pharmaceutical Industries Ltd. announced the approval of Herceptin’s biosimilar, Herzuma, in October 2016. As a result, both companies got benefit from the sales of Herzuma. Also, Amgen Inc., Sandoz International GmbH, Samsung Bioepis, and Mylan N.V. jointly launched adalimumab in 2018 in the European biosimilars market and they are expected to launch this biosimilar in the U.S. market by 2023.

Some of the key players in the global biosimilars market are AMEGA Biotech, Samsung Bioepis Co. Ltd., Coherus BioSciences Inc., Synthon Holding B.V., BIOCAD, Zydus Cadila, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., and Mylan N.V.
Global Biosimilars Market Segmentation
Market Segmentation by Product
• Recombinant Glycosylated Proteins
o Monoclonal antibodies (mAbs)
o Erythropoietin
o Follitropin
• Recombinant Non-Glycosylated Proteins
o Insulin
o Recombinant human growth hormone
o Granulocyte-colony stimulating factor (G-CSF)
o Interferons
• Recombinant Peptides
Market Segmentation by Technology
• Monoclonal Antibody (mAb)
• Recombinant Deoxyribonucleic Acid (rDNA)
• Bioassays
• Nuclear Magnetic Resonance (NMR)
• Electrophoresis
Market Segmentation by Indication
• Oncology
• Rheumatology
• Blood-Related Disorders
• Auto-Immune Diseases
• Chronic Diseases
• Infectious Diseases
• Growth Hormone Deficiency (GHD)
• Others
Market Segmentation by Manufacturing Type
• Contract
• In-House
Market Segmentation by Route of Administration (ROA)
• Intravenous
• Subcutaneous
• Intranasal
• Others
Market Segmentation by Geography
• Europe Biosimilars Market
o By product
o By technology
o By indication
o By manufacturing type
o By ROA
o By country – Germany, France, U.K., Italy, Spain, Sweden, Russia, Switzerland, Austria, Netherlands, Belgium, Norway, and Rest of Europe
• Asia-Pacific (APAC) Biosimilars Market
o By product
o By technology
o By indication
o By manufacturing type
o By ROA
o By country – China, Japan, India, South Korea, Singapore, Australia, Thailand, Indonesia, Malaysia, and Rest of APAC
• North America Biosimilars Market
o By product
o By technology
o By indication
o By manufacturing type
o By ROA
o By country – U.S. and Canada
• Latin America (LATAM) Biosimilars Market
o By product
o By technology
o By indication
o By manufacturing type
o By ROA
o By country – Brazil, Mexico, Argentina, Columbia, and Rest of LATAM
• Middle East & Africa (MEA) Biosimilars Market
o By product
o By technology
o By indication
o By manufacturing type
o By ROA
o By country – U.A.E., Israel, South Africa, Saudi Arabia, and Rest of MEA

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.